
Our principal aims are to study the genetics of the Spanish ALS population, to discover new prognostic and diagnostic biomarkers, and to develop preclinical and clinical assays.
Contact
LocationUniversity Hospital 12 de Octubre, Avenida de Córdoba, Madrid, Spain
Contact
Our Specialists
Current trials
Recruiting
Phase iii
PHOENIX trial
Industry trial
Amylyx Pharmaceuticals Inc is conducting a phase 3 trial to determine the safety and efficacy of their compound 'AMX0035' for the treatment of ALS.
Recruiting
Phase iii
ADORE Trial
Industry trial
Ferrer is conducting a phase 3 trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS).
Recruiting
Phase iii
COURAGE-ALS Trial
Industry trial
In the COURAGE-ALS study, we are investigating the efficacy and safety of the drug ‘reldesemtiv’ for the treatment of ALS. This clinical trial is sponsored by Cytokinetics.
Active
Phase ii
APL2-ALS-206 Trial
Industry trial
In this phase 2 study, we are investigating the safety and efficacy of the drug pegcetacoplan for the treatment of ALS. This trial is sponsored by Apellis Pharmaceuticals.
Active
Phase ii
RT001 in Amyotrophic Lateral Sclerosis
Industry trial
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
Recruiting
Phase iii
TUDCA-ALS
Investigator initiated trial
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.